Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

The success of immunotherapy in oncology underscores the vital role of the immune system
in cancer development. Regulatory T cells (Tregs) maintain a fine balance between …

Antibody therapies have become an important class of therapeutics in recent years as they
have exhibited outstanding efficacy and safety in the treatment of several major diseases …

Several therapeutic monoclonal antibodies (mAbs), including those targeting epidermal
growth factor receptor, human epidermal growth factor receptor 2 (HER2), and CD20 …

The immune checkpoint cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is an
inhibitory regulator of T-cell mediated responses that has been investigated as target of …

IgG glycosylation is currently at the forefront of both immunology and glycobiology, likely due
in part to the widespread and growing use of antibodies as drugs. For over four decades, it …

Antibody dependent cellular cytotoxicity (ADCC) is an Fc-dependent effector function of IgG
important for anti-viral immunity and anti-tumor therapies. NK-cell mediated ADCC is mainly …

Myeloid cells in the tumor microenvironment (TME) can exist in immunosuppressive and
immunostimulatory states that impede or promote antitumor immunity, respectively. Blocking …